Biotechnology company Agenus Inc. and others are entitled to dismissal of a proposed class action alleging it violated securities laws by misleading investors about the effectiveness of an immuno-oncology product to treat colon cancer, a Massachusetts federal district court said.
Bryon Olsen, who sued in 2024, failed to adequately allege facts with particularity establishing false or misleading statements or loss causation, Judge Angel Kelley of the US District Court for the District of Massachusetts said in a Monday order granting a motion to dismiss.
The company develops immunotherapy treatments, including balstilimab and botensilimab to treat certain types of cancer.
Agenus ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.